Relispray Antifungal Liquid Aerosol, Spray
NDC Package 46063-810-12
Package Information
Relispray Antifungal Liquid (tolnaftate) aerosols is wash the affected area and dry thoroughlyshake can well and apply a thin layer over the affected area twice daily (morning and night)supervise children in the use of this productfor athlete's foot:pay special attention to spaces between the toeswear well-fitting, ventilated shoeschange shoes and socks at least once dailyfor athlete's foot and ringworm: use daily for 4 weeksfor jock itch, use daily for 2 weeksif condition persists longer, consult a doctorthis product is not effective on the scalp or nails. This formulation utilizes a aerosol, spray delivery system. Marketed by Midas-care Pharmaceuticals Pvt. Ltd., this product is identified by NDC 46063-810 and is authorized under FDA application M005.
Identification & Billing
- RxCUI: 313421 - tolnaftate 1 % Topical Spray
- RxCUI: 313421 - tolnaftate 10 MG/ML Topical Spray
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 46063 - Midas-care Pharmaceuticals Pvt. Ltd.
- 46063-810 - Relispray Antifungal Liquid
- 46063-810-12 - 128 g in 1 CAN
- 46063-810 - Relispray Antifungal Liquid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 46063-810-12 identifies a specific commercial package of 128 g in 1 can of Relispray Antifungal Liquid, a human over the counter drug labeled by Midas-care Pharmaceuticals Pvt. Ltd.. This aerosol, spray is formulated for topical use and contains tolnaftate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Midas-care Pharmaceuticals Pvt. Ltd. on March 01, 2022. The current certification is valid through December 31, 2026.
How is this Midas-care Pharmaceuticals Pvt. Ltd. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 46063081012. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.